WO2025041080 - SELENIUM DEFICIENCY ANALYSIS AND TREATMENTS
National phase entry is expected:
Publication Number
WO/2025/041080
Publication Date
27.02.2025
International Application No.
PCT/IB2024/058188
International Filing Date
22.08.2024
Title **
[English]
SELENIUM DEFICIENCY ANALYSIS AND TREATMENTS
[French]
ANALYSE ET TRAITEMENTS D'UNE DÉFICIENCE EN SÉLÉNIUM
Applicants **
PHILERA NEW ZEALAND LTD.
SCHOLEFIELD, Melissa
Inventors
FORTUNAK, Joseph
COOPER, Garth
Priority Data
63/534,068
22.08.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2908 | |
| EPO | Filing, Examination, Granting | 20696 | |
| Japan | Filing, Examination, Granting | 2649 | |
| South Korea | Filing, Examination, Granting | 3023 | |
| USA | Filing, Examination, Granting | 8110 |
Total:
37,386
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided herein are methods of assessing selenium deficiency in subjects having Huntington's Disease. Further provided herein are methods of treating and/or preventing Huntington's Disease by administering pharmaceutical compositions comprising selenium agents.[French]
L'invention concerne des procédés d'évaluation d'une déficience en sélénium chez des sujets atteint de la maladie de Huntington. L'invention concerne en outre des méthodes de traitement et/ou de prévention de la maladie de Huntington par administration de compositions pharmaceutiques comprenant des agents sélénium.